Insider Buying: Turn Therapeutics (NASDAQ:TTRX) Director Buys 20,532 Shares of Stock

Turn Therapeutics Inc. (NASDAQ:TTRX) Director Arthur Golden bought 20,532 shares of the business’s stock in a transaction on Friday, November 21st. The stock was bought at an average price of $2.87 per share, for a total transaction of $58,926.84. Following the transaction, the director directly owned 50,734 shares of the company’s stock, valued at approximately $145,606.58. This represents a 67.98% increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Turn Therapeutics Trading Up 1.5%

Shares of TTRX traded up $0.05 during trading hours on Monday, reaching $3.32. The stock had a trading volume of 18,004 shares, compared to its average volume of 776,973. Turn Therapeutics Inc. has a 12 month low of $2.57 and a 12 month high of $26.50.

Turn Therapeutics (NASDAQ:TTRX) last issued its quarterly earnings data on Thursday, November 13th. The company reported ($0.07) earnings per share for the quarter.

About Turn Therapeutics

We are a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. Our patented mixing process — commercially referred to as PermaFusion™ (“PermaFusion”) — enables stable suspension of polar, water-soluble active pharmaceutical ingredients (“APIs”) in oil-based carriers without the use of emulsifiers.